KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Assets (2017 - 2025)

Bionano Genomics' Assets history spans 7 years, with the latest figure at $79.1 million for Q3 2025.

  • For Q3 2025, Assets fell 9.5% year-over-year to $79.1 million; the TTM value through Sep 2025 reached $79.1 million, down 9.5%, while the annual FY2024 figure was $76.7 million, 64.24% down from the prior year.
  • Assets for Q3 2025 was $79.1 million at Bionano Genomics, up from $76.0 million in the prior quarter.
  • Across five years, Assets topped out at $384.9 million in Q1 2021 and bottomed at $76.0 million in Q2 2025.
  • The 5-year median for Assets is $271.4 million (2023), against an average of $232.8 million.
  • The largest annual shift saw Assets surged 1914.77% in 2021 before it tumbled 64.24% in 2024.
  • A 5-year view of Assets shows it stood at $377.1 million in 2021, then fell by 18.46% to $307.5 million in 2022, then plummeted by 30.28% to $214.4 million in 2023, then crashed by 64.24% to $76.7 million in 2024, then rose by 3.12% to $79.1 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Assets are $79.1 million (Q3 2025), $76.0 million (Q2 2025), and $78.4 million (Q1 2025).